Loading
One look at the lower bowel with a short scope, offered once between 55 and 64, cut bowel cancer cases by a quarter and deaths by a third in a UK trial of 170,432 people.
The UK Flexible Sigmoidoscopy Trial, run in 14 UK centres by Atkin, Edwards, Kralj-Hans and colleagues, randomly allocated 170,432 men and women who had said on a previous questionnaire that they would accept screening to be offered one flexible sigmoidoscopy or not to be contacted at all. Randomisation was in blocks of 12, stratified by trial centre, general practice and household type. The primary outcomes were colorectal cancer incidence, including cases found at screening, and colorectal cancer mortality.
40,674 of the 57,099 people in the intervention group (71 percent) underwent the test. Over a median 11.2 years, 2,524 participants were diagnosed with colorectal cancer and 727 deaths were certified from it.
The trial behind England's short-lived bowel scope screening programme, and the clearest demonstration that one endoscopic look, by removing adenomas, prevents cancer rather than only advancing its diagnosis.
Shares Endoscopy (EGD, EUS, ERCP), Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Prevention we already have is not deployed, The Lancet and the tag colorectal-evidence.
Shares Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up, Endoscopy (EGD, EUS, ERCP), Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Cancer Research UK and the tag colorectal-evidence.
Shares Endoscopy (EGD, EUS, ERCP), Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Prevention we already have is not deployed, The hardest cancers are found late and the tag colorectal-evidence.
Shares Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), The Lancet, The hardest cancers are found late, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation and the tag colorectal-evidence.
Shares Endoscopy (EGD, EUS, ERCP), Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Prevention we already have is not deployed, The hardest cancers are found late and the tag colorectal-evidence.
Shares Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Prevention we already have is not deployed, The hardest cancers are found late, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation and the tag colorectal-evidence.
Shares Endoscopy (EGD, EUS, ERCP), Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), The hardest cancers are found late, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation and the tag colorectal-evidence.
Shares Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Prevention we already have is not deployed, The hardest cancers are found late, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation and the tag colorectal-evidence.